Riding on Novo Nordisk’s semaglutide, India’s weight-loss market triples in size in 2 years

Semgalutide has almost 66 percent of the market share in the anti-obesity segment.

Top 100 Best Sellers

Read More

​ Semgalutide has almost 66 percent of the market share in the anti-obesity segment. Semgalutide has almost 66 percent of the market share in the anti-obesity segment.  Moneycontrol Latest News Read More